Scholarlink

<p>In the overactivation of the complement, the role of classical pathway is still not thoroughly investigated in COVID-19. Our aim was to examine the connection between SARS-CoV-2-specific antibodies, <i>in vitro</i> complement activation, and <i>in vivo</i> complement profiles in COVID-19 severity groups. Significant differences were detected in the <i>in vitro</i> complement deposition (C3b and C4b) between patients with or without SARS-CoV-2-specific antibodies in each COVID-19 severity group. Interestingly, we could detect <i>in vitro</i> complement depositions <i>via</i> nucleocapsid (N) protein without N-specific antibodies. Furthermore, no differences were detected in the levels of specific antibodies among the whole COVID-19 groups. <i>In vitro </i>complement activation by spike (S) protein was only detected with high S-specific IgG. Next, <i>in vivo</i> complement biomarkers were compared in samples with low or high C3b, C4b depositions. Although, SARS-CoV-2-specific IgG and IgM were strongly associated with <i>in vitro</i> complement deposition, it was only C3a and factor B that was elevated in samples with high <i>in vitro</i> N-induced C3b deposition. In conclusion, <i>in vitro</i> C3b and C4b depositions by S- and N-proteins were associated with the presence of SARS-CoV-2-specific antibodies. Furthermore, convalescence and severely ill patients with specific antibodies showed slight difference in <i>in vitro </i>C4b deposition <i>via</i> nucleocapsid protein.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

In vitro complement activation via nucleocapsid and spike proteins of SARS-CoV-2 in COVID-19 patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月22日

查看全文
  • Petra Kiszel,
  • János Miklós,
  • Erika Kajdácsi,
  • György Sinkovits,
  • László Cervenak,
  • Zoltán Prohászka

摘要

In the overactivation of the complement, the role of classical pathway is still not thoroughly investigated in COVID-19. Our aim was to examine the connection between SARS-CoV-2-specific antibodies, in vitro complement activation, and in vivo complement profiles in COVID-19 severity groups. Significant differences were detected in the in vitro complement deposition (C3b and C4b) between patients with or without SARS-CoV-2-specific antibodies in each COVID-19 severity group. Interestingly, we could detect in vitro complement depositions via nucleocapsid (N) protein without N-specific antibodies. Furthermore, no differences were detected in the levels of specific antibodies among the whole COVID-19 groups. In vitro complement activation by spike (S) protein was only detected with high S-specific IgG. Next, in vivo complement biomarkers were compared in samples with low or high C3b, C4b depositions. Although, SARS-CoV-2-specific IgG and IgM were strongly associated with in vitro complement deposition, it was only C3a and factor B that was elevated in samples with high in vitro N-induced C3b deposition. In conclusion, in vitro C3b and C4b depositions by S- and N-proteins were associated with the presence of SARS-CoV-2-specific antibodies. Furthermore, convalescence and severely ill patients with specific antibodies showed slight difference in in vitro C4b deposition via nucleocapsid protein.